Dominik Lott1,2, Andreas Krause3, Christian A Seemayer4, Daniel S Strasser5, Jasper Dingemanse3, Thorsten Lehr6. 1. Department of Clinical Pharmacy, Saarland University, Saarbrücken, Germany. Dominik.Lott@actelion.com. 2. Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland. Dominik.Lott@actelion.com. 3. Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland. 4. Department of Global Clinical Science and Epidemiology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. 5. Department of Translational Science Biology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. 6. Department of Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Abstract
PURPOSE: This analysis aimed at describing the effect of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod on lymphocyte subsets in peripheral blood. As the involvement of different lymphocyte subsets varies among different autoimmune diseases, characterizing the effect of ponesimod on these may be beneficial in better understanding treatment effects. METHODS: Three phase 1 clinical studies in healthy human subjects were pooled. Non-linear mixed-effects modeling techniques were used to study the effect of ponesimod on lymphocyte subsets such as B cells, T helper cells, T cytotoxic cells, and natural killer cells in a qualitative and quantitative manner. RESULTS: Indirect-response Imax models including circadian variation best described the effect of ponesimod on lymphocyte subsets. B cells and T helper cells were shown to be more affected compared to T cytotoxic cells with respect to the maximum possible reduction (100% for B and T helper cells, 95% for T cytotoxic cells) and the concentration required to reach half the maximum effect. Inter-individual variability was found to be larger for T cytotoxic compared to T helper, and B cells. CONCLUSION: These first models for ponesimod on the level of lymphocyte subsets offer a valuable tool for the analysis and interpretation of results from ponesimod trials in autoimmune diseases.
PURPOSE: This analysis aimed at describing the effect of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod on lymphocyte subsets in peripheral blood. As the involvement of different lymphocyte subsets varies among different autoimmune diseases, characterizing the effect of ponesimod on these may be beneficial in better understanding treatment effects. METHODS: Three phase 1 clinical studies in healthy human subjects were pooled. Non-linear mixed-effects modeling techniques were used to study the effect of ponesimod on lymphocyte subsets such as B cells, T helper cells, T cytotoxic cells, and natural killer cells in a qualitative and quantitative manner. RESULTS: Indirect-response Imax models including circadian variation best described the effect of ponesimod on lymphocyte subsets. B cells and T helper cells were shown to be more affected compared to T cytotoxic cells with respect to the maximum possible reduction (100% for B and T helper cells, 95% for T cytotoxic cells) and the concentration required to reach half the maximum effect. Inter-individual variability was found to be larger for T cytotoxic compared to T helper, and B cells. CONCLUSION: These first models for ponesimod on the level of lymphocyte subsets offer a valuable tool for the analysis and interpretation of results from ponesimod trials in autoimmune diseases.
Entities:
Keywords:
B cells; PK/PD modeling; T cells; lymphocyte subsets; sphingosine-1-phosphate receptor
Authors: Luca Piali; Sylvie Froidevaux; Patrick Hess; Oliver Nayler; Martin H Bolli; Eva Schlosser; Christopher Kohl; Beat Steiner; Martine Clozel Journal: J Pharmacol Exp Ther Date: 2011-02-23 Impact factor: 4.030
Authors: Tomas Olsson; Aaron Boster; Óscar Fernández; Mark S Freedman; Carlo Pozzilli; Doris Bach; Ouali Berkani; Markus S Mueller; Tatiana Sidorenko; Ernst-Wilhelm Radue; Maria Melanson Journal: J Neurol Neurosurg Psychiatry Date: 2014-03-21 Impact factor: 10.154